After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
He added that the company's plan to sell Foundayo through government channels will depend on the pricing implications of the ...
German generics maker Stada is back to business after being acquired by CapVest Partners last year, loading itself up with 16 ...
AdvanCell, a clinical-stage radiopharmaceutical developer, has inked a lease near Boston to produce its prostate cancer ...
Julianne Hough is the new face of Revance’s Botox rival Daxxify. | Julianne Hough is the new face of Revance’s Botox rival ...
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC ...
It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its cl ...
The move will lead to layoffs for around 17% of ADC Therapeutics’ global workforce, with the aim to achieve around $10 million a year in savings, the company said in a Jun. 24 release. (Stock ...
As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world ...
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products ...
A newly unsealed whistleblower lawsuit accuses Novartis and Genentech of being at the center of a decades-long kickback ...
Pharma companies have been part of the global economy and our health systems for centuries. | Pharma companies have been part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results